Product
Ibrexafungerp
3 clinical trials
12 indications
Indication
Vulvovaginal CandidiasisIndication
Invasive CandidiasisIndication
Mucocutaneous CandidiasisIndication
Valley FeverIndication
HistoplasmosisIndication
BlastomycosisIndication
Chronic Pulmonary AspergillosisIndication
Allergic Bronchopulmonary AspergillosisIndication
Invasive Pulmonary AspergillosisIndication
Recurrent Vulvovaginal CandidiasisIndication
Emerging FungiIndication
Fungal infectionClinical trial
Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole TherapyStatus: Completed, Estimated PCD: 2023-05-16
Clinical trial
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)Status: Completed, Estimated PCD: 2023-08-17
Clinical trial
A Phase 1, Open-Label, Single-Centre Study to Evaluate the Absorption, Distribution, Metabolism and Excretion (ADME) of Oral [14^C]-Ibrexafungerp in Healthy Male Subjects After Repeat DosingStatus: Completed, Estimated PCD: 2023-01-28